ASCO Grants IDYA Late‑breaker Despite Extensive Prior Data
Given how much $IDYA has already released (ORR, PFS, stats, PFS curves) I'm a little surprised #ASCO26 is OK with giving it a late-breaker.
RG6735 Identified as New $RHHBY Phase‑1 Asset
Any idea what RG6735 is? Looks like a new $RHHBY code for sth that went into phase 1 earlier under a different name. https://t.co/7Cb5Ft2BWC
LLY's Second in Vivo CAR‑T Deal via Kelonia Buyout
Kelonia turns #ASH25 late-breaker into buyout, with $LLY's second move into in vivo Car-T. Via @ApexOnco -> https://t.co/NPhdnuhPu3 $AZN $GILD
LLY Acquires Kelonia for $3.25bn After ASH25 Insights
It's official: $LLY buying Kelonia for $3.25bn + milestones. @ByMadeleineA take on the #ASH25 dataset that triggered this move: https://t.co/nVUNlq7YlO
JNJ's HLD-0117 Enters Phase 1, Target Unreve
Second $JNJ ex-Halda "riptac", HLD-0117, goes into phase 1. Previously only known as "breast cancer riptac", target still undisclosed https://t.co/aJRe55AgYH
AZD4956
Just disclosed in #AACR26 abstracts: $AZN AZD4956 = DNA pol theta inhibitor. My story from when it entered phase 1/2 Parthenon study +/-saruparib -> https://t.co/bHoOKqd7da
RVMD and ALLO Illustrate Biotech's Enduring Success Struggle
Why $RVMD & $ALLO are a microcosm of biotech's historic struggle for success. Some musings from me on @ApexOnco -> https://t.co/3lWgzQplvc
ALLO May
Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8
NVS Sells Darovasertib for $6M in Cash, Stock
Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.
ALLO's Alpha-3 DLBCL Data Set to Spark Pre‑Market Move
Key $ALLO catalyst coming pre market today, with first data from cema-cel's Alpha-3 study in DLBCL consolidation. What to look for: https://t.co/a19BVEppqP
Darovasertib Shows Promise in Optimum-02 Uveal Melanoma Trial
$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa
Investors Demand Immediate Release of Market-Sensitive Data
This is getting quite tiresome: first $ORIC, now $ALLO & $IDYA. Why are you sitting on market-sensitive data rather than releasing it now? https://t.co/N8q95re7ho
IPHYF Falls Short of Promise, Future Uncertain
Of all the IO companies I've met and covered in the past ~15 years I'm struggling to think of one that's been more disappointing vs its initial promise than $IPHYF. Will it even last beyond Q3? Via @ByMadeleineA -> https://t.co/DepdZfDBdY
Prescribing CORT Lifyorli Differs From Cushing’s Experience
Here's prescribing info for $CORT Lifyorli -> https://t.co/i46Whl5lX6 Why so different from the experience in Cushing's? https://t.co/EqvbCApqHn
MRK Likely to Rerun TERN Study for Data
Based on previous form $MRK will probably now rerun the $TERN study, just to prove to itself that the data were real.
TERN's Termination Terms Hint MRK Could Be Outbid
For those wondering if $MRK might be outbid, here are the deal termination terms from $TERN https://t.co/TbM3rWyEoG
US Patients Access Zegfrovy via Apex Oncology
Another win for Dizal, but how do US patients get hold of Zegfrovy? Via @ApexOnco -> https://t.co/4GVjyHS9vz https://t.co/bjjrnZkNL6
NVS
$NVS paying $2bn for Synnovation's SNV4818, after $LLY paid $1.5bn for Scorpion's STX-478. Mechanistically, seems like good news for $RLAY, bad for $OKUR & $COGT
MRK Unveils PD-1/VEGF Bispecific at AACR26
$MRK's PD-1 x VEGF bispecific reveal, & other key #AACR26 presentations, via @APEXONCO -> https://t.co/ob1eswxCWF $RVMD $AMGN $GILD $BCYC $SDGR
Correct Lung Target, Yet IMMP’s
Lung (not head & neck) was the right choice for $IMMP to pursue in phase 3, but it still failed. Stock -89%. Sory via @APEXONCO -> https://t.co/Y1ilGP5Aqq
Servier's $2.5B DAWN Deal Closes Ojemda Saga
$DAWN acquisition by Servier for $2.5bn is quite the ending for Ojemda. Who remembers this RAF inhibitor's bizarre & convoluted history? $BIIB $TAK https://t.co/uD5drO9ymr
HMPL‑A580 Confirmed as Anti‑EGFR ADC, Impacts ALXO
I speculated last month that HMPL-A580 was an anti-EGFR ADC https://t.co/XFDtZfWWkH and $HCM just confirmed that this is the case. Relevant for $ALXO
CTMX Soars 660% Ahead of Masked ADC Catalyst
$CTMX, +660% in 12 months, approaches its masked ADC catalyst. Via @ApexOnco -> https://t.co/oQI1iQiV4N ( $JANX -58% in the same timeframe)
Flare's GU26 Targets Undruggable PPAR‑γ, Yet Caveats Remain
Who's heard of Flare Therapeutics? #GU26 late-breaker shows promise in hitting "undruggable" PPAR-γ target, with a few major caveats. Via @ApexOnco -> https://t.co/1GepvywtL0
MRK's Ovarian Cancer Claim Rejected by FDA, EMA
$MRK claims a survival benefit in ovarian cancer irrespective of PD-L1 status, but FDA & EMA say BS. Via @ApexOnco -> https://t.co/Cld1O7Uuvp #ESGO26
Welireg Poised to Broaden Reach per GU26 Data
$MRK Welireg could be about to expand its reach at last. #GU26 data via @ApexOnco with relevance to $RCUS -> https://t.co/k59284INdK
RVMD Switches PRMT5 Partner From T
$RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN still dose optimising.)
BCAX's Phase 3 Ficera Dose Raises Critical Concerns
Why is $BCAX testing a ficera dose in phase 3 that it now says isn't optimal (and other uncomfortable questions)? Via @ApexOnco -> https://t.co/mLWKP6AAZ9 $JNJ $GMAB
ASCO GU26 Highlights Litespark, Keynote B15, Flare
Key late-breakers at Asco #GU26 include Litespark-011 & 022, Keynote-B15... and who's heard of Flare Therapeutics? Via @ApexOnco -> https://t.co/bXcANMQu5m $MRK $PFE $ALMPF $CGON $VIR
E
So $LLY not interested in oncology applications of Orna's in vivo Car-T? $ABBV $AZN $BMY $GILD https://t.co/wB3rR5LID8
China Limits Keytruda to dMMR, US Not Restricted
Interesting difference: the corresponding US approval has no restriction to dMMR (remember PFS HR=0.60 in pMMR, but 0.30 in dMMR) $MRK
ApexOnco IPO Highlights Valuation Benchmarks for Biotech
$EIKN prices at $18/share, to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI
Novartis Halts PIT565 T‑cell Engager Development
Confirmned discontinuation of $NVS PIT565, which seems to be a specifically targeted T-cell engager (also hit CD2). cf $AZN Titan platform.
DSNKY's DS-3790 DXd ADC Begins Clinical Trials
$DSNKY's first DXd ADC for haematology, DS-3790, enters the clinic. As I reported last November: https://t.co/9CcbISqbqK
New Antibody‑Drug Conjugates Unveiled in Latest Scoop
Several scoops among the latest ADC names. Via @ApexOnco with H/T to @raffcolo -> https://t.co/JxDmId0Q0A
MRK's Interpath-001 Study Fully Enrolled
$MRK confirming that Interpath-001 study of $MRNA partnered intismeran autogene is "ongoing & fully enrolled". No further guidance as to timing of results, due some time in 2026. My earlier take on what to expect: https://t.co/9Pk3JK8TLs
Leaked Data Reveals Mechanisms of JNJ and MRK ADCs
With a tipoff from a friend, and some info that probably shouldn't have been posted in a trial registry, the mechanisms of ADCs JNJ-95437446 $JNJ & SKB571/ MK-2750 $MRK have been revealed. Quite amazing given the recent $GMAB news. Via...
SNY Drops Alphamedix, Opening Window for CATX
Looks like $SNY discontinued Alphamedix/ SAR447873, licensed in Sep 2024 from Radiomedix & Orano Med, h/t B Riley. @ByMadeleineA covered it at #Esmo25 and flagged dysphagia & renal tox. https://t.co/6L2O0c5cOA Good news for $CATX?
Qilu Mirrors JNJ with New CD79b‑CD20 Trispecific
Qilu appears to be aping $JNJ in trispecific T-cell engagers. First BCMA x GPRC5D, now CD79b x CD20. Via @ApexOnco -> https://t.co/d4pBcl0MuF
ATRA Rallies at JPM26, Eyes Upcoming FDA CRL
#JPM26 off to a great start for $ATRA. Looking forward to the FDA publishing the latest CRL.
Oncology IPO Outspends AKTS, $800M Funding, $205M R&D
So a nice first day trading for $AKTS, +24%, but here comes an oncology IPO of a quite different order: Eikon has had $800m private money invested in it so far (vs $140m for AKTS), and blew $205m on R&D...